Cue Biopharma Inc (CUE)

$0.33 -0.01 (-2.91%)
Market Cap 26.36M
Revenue (ttm) 9.29M
Net Income (ttm) -40.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -437.78%
Debt to Equity Ratio 0.12
Volume 480,400
Avg Vol 1,366,538
Day's Range N/A - N/A
Shares Out 78.74M
Stochastic %K 10%
Beta 1.47
Analysts Strong Sell
Price Target $4.00

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2680
Address:
40 Guest Street, Boston, United States
VinWeezel
VinWeezel Feb. 3 at 3:31 PM
$CUE
0 · Reply
Fixer00
Fixer00 Jan. 29 at 10:15 PM
$CUE They only got 35 views on the post. Very under the radar.
1 · Reply
Fixer00
Fixer00 Jan. 29 at 10:14 PM
$CUE they posted an update on X regarding cue401. https://x.com/cuebiopharma/status/2016873973892387093?s=46
1 · Reply
VinWeezel
VinWeezel Jan. 29 at 1:27 PM
$CUE got a slew of this now…
0 · Reply
Fixer00
Fixer00 Jan. 27 at 8:48 PM
$CUE getting ready
0 · Reply
Fixer00
Fixer00 Jan. 27 at 3:37 PM
$CUE
0 · Reply
VinWeezel
VinWeezel Jan. 27 at 1:07 PM
$CUE today I believe .40s come and stay.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 26 at 3:09 PM
$CUE Current Stock Price: $0.37 Contracts to trade: $1.0 CUE Feb 20 2026 Call Entry: $0.05 Exit: $0.08 ROI: 78% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fixer00
Fixer00 Jan. 26 at 3:51 AM
$CUE .4288
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 4:17 AM
$CUE
0 · Reply
Latest News on CUE
Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 19, 2025, 8:00 AM EST - 6 weeks ago

Cue Biopharma Announces Pricing of $10 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Dec 18, 2025, 4:02 PM EST - 6 weeks ago

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 4:05 PM EST - 2 months ago

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Nov 6, 2025, 8:00 AM EST - 3 months ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Sep 29, 2025, 9:00 AM EDT - 4 months ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 21, 2025, 8:00 AM EDT - 5 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 13, 2025, 8:00 AM EDT - 6 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 16, 2025, 8:00 AM EDT - 7 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jul 1, 2025, 4:05 PM EDT - 7 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Jun 24, 2025, 4:48 PM EDT - 8 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 12, 2025, 4:05 PM EDT - 9 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 8, 2025, 8:00 AM EDT - 9 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

May 5, 2025, 10:00 AM EDT - 9 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 6:12 PM EDT - 10 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 15, 2025, 2:00 AM EDT - 10 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 10:23 PM EDT - 10 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma to Host Business Update Call and Webcast

Apr 14, 2025, 5:02 PM EDT - 10 months ago

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 31, 2025, 4:20 PM EDT - 11 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma Announces Strategic Organizational Transition

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Feb 29, 2024, 10:00 AM EST - 2 years ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 11, 2023, 3:32 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Cue Biopharma to Host Investor Call

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 11:00 PM EDT - 3 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

VinWeezel
VinWeezel Feb. 3 at 3:31 PM
$CUE
0 · Reply
Fixer00
Fixer00 Jan. 29 at 10:15 PM
$CUE They only got 35 views on the post. Very under the radar.
1 · Reply
Fixer00
Fixer00 Jan. 29 at 10:14 PM
$CUE they posted an update on X regarding cue401. https://x.com/cuebiopharma/status/2016873973892387093?s=46
1 · Reply
VinWeezel
VinWeezel Jan. 29 at 1:27 PM
$CUE got a slew of this now…
0 · Reply
Fixer00
Fixer00 Jan. 27 at 8:48 PM
$CUE getting ready
0 · Reply
Fixer00
Fixer00 Jan. 27 at 3:37 PM
$CUE
0 · Reply
VinWeezel
VinWeezel Jan. 27 at 1:07 PM
$CUE today I believe .40s come and stay.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 26 at 3:09 PM
$CUE Current Stock Price: $0.37 Contracts to trade: $1.0 CUE Feb 20 2026 Call Entry: $0.05 Exit: $0.08 ROI: 78% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fixer00
Fixer00 Jan. 26 at 3:51 AM
$CUE .4288
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 4:17 AM
$CUE
0 · Reply
Fixer00
Fixer00 Jan. 24 at 12:12 AM
$CUE we are rocking on Monday
1 · Reply
Fixer00
Fixer00 Jan. 23 at 6:10 PM
$CUE looks like they will run this into close.
0 · Reply
VinWeezel
VinWeezel Jan. 23 at 5:11 PM
$CUE
0 · Reply
taneraydar
taneraydar Jan. 23 at 3:20 AM
$CUE overnight .47
0 · Reply
Zero11
Zero11 Jan. 22 at 9:59 PM
$CUE for those of you wondering why this is moving with no news it’s because of the Cue-100 trial. Iykyk
0 · Reply
Kesiya
Kesiya Jan. 22 at 9:16 PM
$CUE CUE
0 · Reply
CloudKing
CloudKing Jan. 22 at 6:53 PM
$CUE LONG
0 · Reply
Relee187200
Relee187200 Jan. 22 at 12:27 PM
$CUE Why moving up some? I don’t see any news.
0 · Reply
Kesiya
Kesiya Jan. 22 at 6:21 AM
📈 Top 5 Premarket Stocks to Watch | Jan 22, 2026 1️⃣ $AREB Float/OS: 7.95M / 7.96M | Fee 75.33% | Avail 550K ➡️ Extremely tight float + very high borrow fee. Strong volatility setup. 2️⃣ $IOBT Float/OS: 33.45M / 71.95M | Fee 4.96% | Avail 2.3M ➡️ Company announced review of strategic alternatives (M&A / asset sale). 3️⃣ $AKTX Float/OS: 33.76M / 48.26M | Fee 8.82% | Avail 5.7M ➡️ Oncology biotech with ADC platform. 2026 milestones in focus. 4️⃣ $AURE Float/OS: 311.02M / 356.69M | Fee 2.69% | Avail 350K ➡️ AI & fintech play. Recent ATM filing = high volume & momentum watch. 5️⃣ $CUE Float/OS: 127.84M / 133.36M | Fee 0.82% | Avail 5.7M ➡️ Immunotherapy biotech. Recently raised capital, watching for base & bounce. ⚠️ High‑risk, high‑volatility momentum names. Not financial advice. Trade with a plan. #Premarket #Stocktwits #Momentum #SmallCaps #Biotech
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 22 at 2:12 AM
$CUE Nice close
0 · Reply
A_LegendaryMan
A_LegendaryMan Jan. 21 at 11:52 PM
Thousand percent these guys! They pegged $AURE yesterday. Nice 30% / 5k win on that one. Still holding some lottos. Got $CUE right when they called it. I keep that community on speed dial.
0 · Reply
gd04
gd04 Jan. 21 at 9:47 PM
$CUE it should run
0 · Reply